Zobrazeno 1 - 10
of 43
pro vyhledávání: '"L, Mitrofan"'
Autor:
Gaëlle Nachbaur, L Benjamin, Isabelle Durand-Zaleski, Rana Maroun, Franck Maunoury, Philippe Le Jeunne, L. Mitrofan
Publikováno v:
BMC Cancer
BMC Cancer, BioMed Central, 2018, 18 (1), pp.214. ⟨10.1186/s12885-018-4117-z⟩
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
BMC Cancer, BioMed Central, 2018, 18 (1), pp.214. ⟨10.1186/s12885-018-4117-z⟩
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Background Patient characteristics and survival outcomes in randomized trials may be different from those in real-life clinical practice. The objective of this study was to describe treatment pathways, safety, drug costs and survival in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f52b64a26002fd642ab69cc566ba2b75
https://www.hal.inserm.fr/inserm-01857845/file/s12885-018-4117-z.pdf
https://www.hal.inserm.fr/inserm-01857845/file/s12885-018-4117-z.pdf
Publikováno v:
Annals of Oncology. 28:xi7-xi8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c739ff49f2dd217e8bfa227290e94789
https://doi.org/10.1093/annonc/mdx711.006
https://doi.org/10.1093/annonc/mdx711.006
Publikováno v:
Current Pharmaceutical Design. 16:2970-2980
Bisphosphonates are a class of drugs developed over the past three decades for the treatment of metabolic bone diseases with high bone turnover, such as Pagets disease, tumor associated osteolysis and osteoporosis. The exceptional pharmacokinetic pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::174d02e5fa2bb777429153b276b66a98
https://doi.org/10.2174/138161210793563644
https://doi.org/10.2174/138161210793563644
Lysosomal-Mitochondrial Axis in Zoledronic Acid-induced Apoptosis in Human Follicular Lymphoma Cells
Publikováno v:
Journal of Biological Chemistry. 285:1967-1979
Bisphosphonates (BPs) are potent inhibitors of osteoclast function, widely used to treat excessive bone resorption associated with bone metastases, that also have anti-tumor activity. Zoledronic acid (ZOL) represents a potential chemotherapeutic agen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78a34c14c85ec2aff8ebcf6b8aabd9d3
https://doi.org/10.1074/jbc.m109.038935
https://doi.org/10.1074/jbc.m109.038935
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
F. Schooneman, J.-J. Huart, T. Verpoort, Daniela Bratosin, F. Goudaliez, L. Mitrofan-Oprea, Carmen Palii, A. Héron, M. Behague, E. Smagghe, Jean-Pierre Tissier, Jean Montreuil
Publikováno v:
Transfusion Clinique et Biologique. 14:393-401
Resume Les recherches que nous avons effectuees ont pour but d’elucider le probleme de la rapide clairance des hematies transfusees en nous fondant sur nos connaissances actuelles des mecanismes de la mort programmee de ces cellules. Materiels et m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0c1b3788e672d240727fedd7b789ac8
https://doi.org/10.1016/j.tracli.2007.05.003
https://doi.org/10.1016/j.tracli.2007.05.003
Autor:
Rana Maroun, Franck Maunoury, P. Le Jeunne, L Benjamin, Gaëlle Nachbaur, Durand-Zaleski, L. Mitrofan
Publikováno v:
Value in Health. 19:A716-A717
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7bbb25713c1efa492a34ed437982a8ad
https://doi.org/10.1016/j.jval.2016.09.2119
https://doi.org/10.1016/j.jval.2016.09.2119
Publikováno v:
Annals of Oncology. 28:v491
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::93e9ba95353e68046634a8accbda3479
https://doi.org/10.1093/annonc/mdx380.076
https://doi.org/10.1093/annonc/mdx380.076
Publikováno v:
Journal of Clinical Oncology. 35:e19004-e19004
e19004 Background: Del (p17) or TP53MUT are important negative prognostic indicators for CLL patients (pts). Using a large European database we evaluated the influence of chemotherapies on the detection of Del (p17) and TP53MUT in advanced CLL pts re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7ee2958fb1e8f2a862bc94b8a034499
https://doi.org/10.1200/jco.2017.35.15_suppl.e19004
https://doi.org/10.1200/jco.2017.35.15_suppl.e19004